Indevus Announces Initiation Of Phase III Clinical Trial Of Octreotide Implant For Acromegaly

Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced the initiation of a Phase III clinical trial of the Company’s novel octreotide implant for acromegaly. This trial is designed to test the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly. The implant utilizes the Company’s patented HYDRON(R) Polymer Technology to deliver effective levels of octreotide for six months.

More: continued here

Filed under: Endocrinology on October 3rd, 2008